Fluzone High-Dose (Sanofi Pasteur) Drug Market Report 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Fluzone High-Dose" report has been added to ResearchAndMarkets.com's offering.

Fluzone HD (inactivated split virion; Sanofi Pasteur) is an inactivated influenza vaccine that contains antigens from two A strains and one B strain specified by the World Health Organization seasonally for influenza vaccination.

The high-dose vaccine is four times more concentrated than the standard Fluzone vaccine, hence providing a higher antibody response. Fluzone HD was approved for use in persons aged =65 years in the US in December 2009.

Research Outlook

The superior efficacy of Fluzone High-Dose (HD) (inactivated split virion trivalent influenza vaccine [TIV]; Sanofi Pasteur) compared to standard-dose inactivated influenza vaccines (IIVs) has positioned it as one of the preferred options for the elderly in the US.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Fluzone High-Dose: Seasonal influenza vaccines

List of Tables

Table 1: Fluzone High-Dose drug profile

Table 2: Approval history of Fluzone HD for seasonal influenza vaccination

Table 3: Late-phase trials of Fluzone HD for seasonal influenza vaccination

Table 4: Fluzone High-Dose for seasonal influenza - SWOT analysis

For more information about this report visit https://www.researchandmarkets.com/r/trhrui

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines